Table 1 Basic characteristics of patient cohorts and controls.

From: Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure

 

HCM

Cohort

Control

DCM/ICM

Conhort

Non-obstructive

Obstructive

DCM/ICM

Control

Number

27

21

20

15

5

Age (year)

45 ± 14

53 ± 13

46 ± 13

56 ± 3

46 ± 10

Male (%)

74

81

70

75

80

NYHF class

I∼II

I∼II

—

III∼IV

—

LVEF (%)

67 ± 8*

72 ± 5*†

61 ± 6

25 ± 2

—

β-blocker use (%)

44

67

—

73

—

  1. HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; ICM: ischemic cardiomyopathy. LVEF: left ventricular ejection fraction. *P < 0.05 vs. control, †P < 0.05 vs. non-obstrutive group.
Back to article page